Milestone Pharmaceuticals enters the post-earnings session with a split signal: shorts retreated sharply ahead of the Q1 print, yet the numbers themselves disappointed.
Short interest collapsed 26% in the week to May 12, dropping from roughly 10.6 million shares to 7.8 million — cutting exposure from around 12% of the float to 9.1%. That is a decisive cover-down, not incremental noise. The move came in the two sessions immediately following the prior week and preceded today's Q1 earnings release, suggesting positioned shorts were unwilling to carry the risk into a catalyst. Borrowing costs barely moved — the rate ticked up to 1.65% APR from about 1.38% a week ago, a modest increase that reflects the lighter short book rather than any borrow squeeze. Availability remains comfortable at 168% of short interest, meaning there is no supply constraint for anyone looking to rebuild a position.
Options positioning is almost unusually calm. The put/call ratio at 0.16 is fractionally above its 20-day average and sits near the lower end of the past year's range, with the 52-week high at 0.75. That near-complete absence of put buying ahead of earnings looks, in hindsight, consistent with a market that expected — or hoped for — something better.
The fundamental story explains the caution. Q1 EPS came in at negative $0.20, missing the estimate of $0.14. Revenue clocked at $238,000, the first quarter of CARDAMYST commercial sales following what has been a long and painful regulatory journey. The bull case centres on that launch trajectory — management highlighted early commercial progress and announced an expansion push into Europe and China, alongside a new AFib trial. The bear case is straightforward: the company is burning cash at a significant rate, its valuation multiples are all deeply negative (EV/EBITDA of -1.6x, trailing P/E of -3.0x), and every target price that analysts set last December at $8.00 now sits roughly four times above the stock's $1.90 close. The four-analyst consensus buy rating and $6.50 mean target are worth noting — though the most recent target update was in January 2026 from HC Wainwright reiterating at $8.00, and targets at that level relative to a $1.90 stock should be treated with scepticism until confirmed post-earnings.
The ORTEX short score eased noticeably this week, dropping from 70.0 to 64.1 as the cover-down registered. Before that, the score had been climbing through April, peaking near 70 as shorts built into the period. The earnings reaction history adds context worth holding: the last time Milestone reported, in March 2026, the stock fell 25.9% on the day and 38.8% over the following five sessions. That prior event followed an earlier regulatory setback and reflects how violent the reaction function can be for a single-asset commercial-stage biotech trading below $2.
Peer context is rough. Close Nasdaq-listed comparables LENZ and AMLX both had difficult weeks, falling 12.8% and 12.1% respectively — so the broader small-cap biotech tape is not providing lift.
The next scheduled event is June 10. Between now and then, what matters most is how fast CARDAMYST revenue scales from its initial $238,000 quarter, whether European regulatory submissions advance on the timeline management outlined, and whether any short sellers who covered ahead of today's print decide the miss changes the risk-reward back in their favour.
See the live data behind this article on ORTEX.
Open MIST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
